State Medicaid group chooses Viekira Pak

Missouri's Medicaid agency said it will make Viekira Pak from AbbVie Inc. (NYSE:ABBV) its preferred regimen to treat HCV in exchange for undisclosed rebates. Missouri is part of a consortium of 24 states plus the District of Columbia that negotiated a rebate on Viekira.

The AbbVie regimen will replace Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) as the

Read the full 580 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE